$CGEN -
Bad movement today,
unfortunately due to a "bad" annual finance report, personally I do think the management has taken a good decision with cost reduction for the next 2 years.
Consolidation of R&D activities in one location (Israel). Positions and operations eliminated will also reduce overlapping R&D and G&A activities in Israel and the United States;
A 35% workforce reduction (approximately 35 employees), the majority of which is in R&D;
Certain preclinical activities will be outsourced to third-party service providers;
IND filing for COM902 in 2019 will proceed as planned. Initiation of the Phase 1 trial for this program will be dependent on the drug combination trials pursued under the collaboration
with Bristol-Myers Squibb as well as available resources to support this trial;
Clinical development and business development activities will continue to operate in the United States; and
Compugen anticipates savings of up to $10 million on an annual basis. Cash expenditures for 2019 including one-time restructuring related costs, are expected to be in the range of $27 to
$29 million, with the full effect of the savings reflected in 2020.
unfortunately due to a "bad" annual finance report, personally I do think the management has taken a good decision with cost reduction for the next 2 years.
Consolidation of R&D activities in one location (Israel). Positions and operations eliminated will also reduce overlapping R&D and G&A activities in Israel and the United States;
A 35% workforce reduction (approximately 35 employees), the majority of which is in R&D;
Certain preclinical activities will be outsourced to third-party service providers;
IND filing for COM902 in 2019 will proceed as planned. Initiation of the Phase 1 trial for this program will be dependent on the drug combination trials pursued under the collaboration
with Bristol-Myers Squibb as well as available resources to support this trial;
Clinical development and business development activities will continue to operate in the United States; and
Compugen anticipates savings of up to $10 million on an annual basis. Cash expenditures for 2019 including one-time restructuring related costs, are expected to be in the range of $27 to
$29 million, with the full effect of the savings reflected in 2020.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.